KEROS THERAPEUTICS INC. - COMMON STOCK

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

09 дек 2024 16:30:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

03 дек 2024 04:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

26 ноя 2024 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

06 ноя 2024 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition

05 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

16 окт 2024 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference

12 сен 2024 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial

03 сен 2024 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

28 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Second Quarter 2024 Financial Results

07 авг 2024 13:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Leadership Updates

17 июн 2024 13:01:02 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

17 июн 2024 03:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Host a Corporate Update Conference Call and Webcast

04 июн 2024 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

03 июн 2024 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

28 май 2024 13:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association

14 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

08 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

14 мар 2024 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

05 мар 2024 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

28 фев 2024 13:01:00 Источник Nasdaq GlobeNewswire